Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.

Antiviral therapy - 1 Aug 2004

Damond Florence, Matheron Sophie, Peytavin Gilles, Campa Pauline, Taieb Audrey, Collin Gilles, Delaunay Christophe, Chêne Geneviève, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to France
Share to HIV-2
Share to HIV Reverse Transcriptase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Tenofovir

Source

Identifiers

PMID: 15456096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.PMID 15456096Read ↗

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.Semantic proximity Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.Semantic proximity Read ↗

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.Semantic proximity Read ↗

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.Semantic proximity Read ↗

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Semantic proximity Read ↗

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.Semantic proximity Read ↗

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.Semantic proximity Read ↗

Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.Semantic proximity Read ↗

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.Semantic proximity Read ↗

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.Semantic proximity Read ↗

The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.